Please provide your email address to receive an email when new articles are posted on . In female-to-male transgender patients, subcutaneous testosterone therapy was safe and effective and was the ...
Please provide your email address to receive an email when new articles are posted on . Laurenzano, Marinkovic and colleagues conducted a retrospective study analyzing subcutaneous testosterone as ...
IRVING, Texas--(BUSINESS WIRE)--In a case study, a 54-year-old male patient with a spontaneous fracture and osteoporosis achieved an “almost complete recovery of osteoporosis” after one year of ...
EWING, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that an abstract on XYOSTED ®, a subcutaneous ...
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone ...
The US Food and Drug Administration (FDA) has approved testosterone enanthate (Xyosted, Antares Pharma) subcutaneous injection for testosterone replacement therapy in men diagnosed with conditions ...
Contraindications to the use of exogenous testosterone formulations, which are Schedule III controlled substances, include prostate cancer (PCa), breast cancer, and/or untreated prolactinoma. 5 TRT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback